Search Videos and More
SRS with Immunotherapy Extends Survival in RCC with Brain Metastasis
According to Manmeet Ahluwalia, MD, MBA, FASCO, kidney cancer currently ranks as the fourth most common cancer to metastasize to the brain after lung cancer, breast cancer, and melanoma.Miami Brain Symposium, Seventh Annual
The Miami Brain Symposium will focus on state-of-the-art approaches to the management of primary and metastatic central nervous systems tumors, along with an understanding of current standards of care and a look at future directions.Minesh P. Mehta, MD, on NSCLC: Tumor Treating Fields for Brain Metastases
Minesh P. Mehta, MD, of Miami Cancer Institute, part of Baptist Health South Florida, discusses results from the METIS (EF-25) trial evaluating the efficacy and safety of tumor treating fields therapy following stereotactic radiosurgery in patients with mutation-negative non–small cell lung cancer (NSCLC) and brain metastases.Miami Cancer Institute Leads First-in-World Brain Metastasis Trial
Baptist Health Miami Cancer Institute is leading a groundbreaking clinical trial that is studying the use of a new medication combined with stereotactic radiosurgery to combat metastatic brain cancer.Miami Cancer Institute Publication Analyzes Role of Tissue-Agnostic Therapies for the Treatment of Primary Brain Tumors
Researchers from Miami Cancer Institute, part of Baptist Health South Florida, recently published a study in Trends in Cancer that analyzes the use of tissue-agnostic therapeutics in patients with primary brain tumors (PBTs). The publication describes the current and potential impact of tissue-agnostic therapies on the management of PBTs. As part of the publication, the researchers discuss data from clinical trials of tissue-agnostic targets for PBTs in the context of challenges in managing these tumors. They also describe additional tissue-agnostic targets that hold promise for benefiting patients with PBTs.Advanced Prostate Cancer: Genetic Testing an Invaluable Tool
A study led by Baptist Health Miami Cancer Institute shows that patients with TP53, RB1 and PTEN mutated prostate cancer have a lower overall survival rate than patients who are biomarker negative. The results emphasize the importance of genetic testing for all advanced cancer patients, the researchers say.Miami Cancer Institute to Host Fifth Global Summit on Immunotherapies for Hematologic Malignancies
Miami Cancer Institute, part of Baptist Health South Florida, announced it will host the Fifth Annual Global Summit on Immunotherapies for Hematologic Malignancies, to be held March 8-9, 2024, at the JW Marriott Hotel in Brickell, Miami, Fla.Miami Cancer Institute Achieves AAHRPP Accreditation
The Association for Accreditation of Human Research Protection Programs has recognized Miami Cancer Institute for promoting ethically sound and safe human subject research practices.Novel Artificial Intelligence Technology Shows Promising Results for Earlier and More Accurate Breast Cancer Detection
Data from the Centers for Disease Control and Prevention highlight that Breast Cancer is second most common form of cancer among women in the U.S. with approximately 240,000 new breast cancer diagnoses each year.Meet the Chief: Music, Sports and Yoga Keep Surgeon Horacio Asbun, M.D., Focused
During his more than 25 years in the field, and as chief of Hepatobiliary and Pancreas Surgery at Baptist Health Miami Cancer Institute since 2018, Horacio Asbun, M.D., has been at the very forefront of global pancreatic cancer research and treatment.Why are More Young Women Being Diagnosed with Lung Cancer Than Young Men?
In a reversal of historic trends, researchers at the American Cancer Society (ACS) have found higher lung cancer incidence in women than in men between the ages of 35 and 54.Paving the Way to New Treatment for Non-Small Cell Lung Cancer that Has Spread to the Brain
Multi-institutional study found that V12 Gy given to radiosurgical volume of larger than 10 cm3 , was a significant predictor of radiation necrosis in patients with brain metastasis from non-small cell lung cancer